The Psychedelic Psychopharmacology Lecture Series


This 5-part workshop series is geared toward providing a foundation for understanding the psychopharmacology and clinical research of the most commonly encountered psychedelic compounds as well as practical information for safe psychedelic use. The series is designed to build upon knowledge gained in previous installments so is recommended to attend them all for an optimal learning experience. Seating is limited so sign up today!


  • June 24, 2019

  • July 25, 2019

  • August 29, 2019

  • September 26, 2019

  • October 24, 2019


  • Doors Open: 6:30pm

  • Lecture: 7:00 - 8:30pm

  • Networking: 8:30 - 9:00pm


Thymele Arts - 5481 Santa Monica Blvd., 2nd Floor, Los Angeles, CA 90029

Series Description:

I.            June 24: Introduction to Psychedelic Psychopharmacology

This first installment in this series is meant to give the participant a foundation that can be used throughout the rest of the series to understand the pharmacology of different types of psychedelic substances. We will begin with an overview of serotonin pharmacology before discussing the two major classes of ‘classic psychedelics’: tryptamines and phenethylamines. From there, we’ll introduce psychedelics that work on different neurotransmitter systems such as ibogaine and ketamine. This installment will finish with a summary of the neuroscientific research that has been conducted with various psychedelics.

II.             July 25: Psychedelic Assisted Psychotherapy (PAP): MDMA & Psilocybin

Both MDMA and psilocybin are being studied as experimental therapies in combination with psychotherapy approaches. Additionally, the Food and Drug Administration (FDA) has designated them both as ‘fast track’ or ‘breakthrough’ therapies. In the second installment, an introduction to psychedelic-assisted psychotherapy will be given prior to a comprehensive discussion of MDMA and psilocybin assisted psychotherapies. Topics covered will include clinical pharmacology, candidate selection, contraindications, and results from trials.

III.            August 29: Psychedelics & Monoamine Oxidase Inhibitors: DMT & 5-MeO-DMT

Monoamine Oxidase (MAO) is an important metabolic enzyme involved in the metabolism of several neurotransmitters and tryptamine psychedelics such as DMT and 5-MeO-DMT. While inhibition of this enzyme is critical to making DMT orally active as part of the mechanism of ayahuasca, it can be unsafe and even lethal to combine other drugs or psychedelics with MAO inhibitors (MAOIs). The third installment of the series will focus on the combination of monoamine oxidase inhibitors (MAOIs) with psychedelics as well as other drugs.

IV.            September 26: Psychedelics Beyond Serotonin: Ibogaine & Ketamine

While most psychedelics produce their effects by modulating serotonin, there are exceptions of worthy mention including ibogaine and ketamine. While vastly different in their effects, both ibogaine and ketamine appear to modulate either glutamate or opioid systems. Ibogaine is often touted for its powerful anti-addictive properties, although it carries risks of cardiotoxicity. Ketamine has built a strong evidence base in the treatment of depression, amongst other refractory conditions. The fourth installment will take a closer look at each of these ‘novel’ psychedelics.

V.            October 24: Psychedelics & Psychotropics: Mechanisms of Drug Interaction

The fifth and last installment in this series will focus exclusively on the potential for drug interactions between psychedelics discussed in installments I–IV and other medications or supplements people may be using. While the aim is to cover a broad range of possible interactions, a focus will be placed on interactions with traditional psychotropics including antidepressants, benzodiazepines, stimulants, and antipsychotics. It is recommended to attend installments I–IV to allow for optimal understanding of materials covered in this installment.

Pricing & Tickets

Purchase Tickets: All Tickets must be pre-purchased online via Eventbrite

  • Individual lecture ticket: $39 (Admission to individual lectures, seating priority will be given to those attending the whole series)

  • Whole series pass: $149 (Includes admission to the entire series with priority seating, as well as PDF handouts of all lecture materials)

  • Whole series + presenter consultation: $209 (Includes admission to the entire series with priority seating, as well as PDF handouts of all lecture materials and 30-minute psychopharmacology consultation with presenter. Consultation scheduled at a time of your convenience.)

  • Student ticket: $25 per session (must present valid student ID at door)